{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&answer.answeringMemberPrinted=Steve+Brine", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&answer.answeringMemberPrinted=Steve+Brine", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&_metadata=all&answer.answeringMemberPrinted=Steve+Brine", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&_page=0&answer.answeringMemberPrinted=Steve+Brine", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&answer.answeringMemberPrinted=Steve+Brine", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&answer.answeringMemberPrinted=Steve+Brine", "items" : [{"_about" : "http://data.parliament.uk/resources/1060965", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1060965/answer", "answerText" : {"_value" : "<p>By 2021, every person diagnosed with cancer will have access, where appropriate, to personalised care, including a needs assessment, a care plan and health and wellbeing information and support. The needs assessment guides a conversation about the person\u2019s holistic needs (physical, psychosocial, financial and social) in order to identify any concerns, including psychological and emotional.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-02-19", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-02-19T17:25:31.79Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-02-14", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer: Counselling"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans the Government has to ensure that people with cancer are able to access psychological and emotional support.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "909320"}
    , {"_about" : "http://data.parliament.uk/resources/1050100", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1050100/answer", "answerText" : {"_value" : "<p>Ten multi-disciplinary diagnostic centres are being piloted through the Accelerate, Co-ordinate, Evaluate (ACE) partnership between Cancer Research UK, Macmillan Cancer Support and NHS England. This pilot programme will end in March 2019. Early findings from those sites informed the plans for roll out of the Rapid Diagnostic Centres as part of the NHS Long Term Plan.<\/p><p> <\/p><p>During 2019/20, the ACE Programme will share further evaluation from the pilot centres. The findings will continue to inform plans for expansion of the Rapid Diagnostic Centres, alongside work being led by Cancer Alliances to improve early diagnosis.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-02-05", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-02-05T15:31:33.267Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-01-28", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Blood Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 March 2018 to Question 134294 on Haematological Cancer, when he plans for the evaluation of the rapid diagnostic centres to be published; and he plans for that evaluation to inform the national roll-out of the centres as proposed in the NHS Long-Term Plan.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "213321"}
    , {"_about" : "http://data.parliament.uk/resources/1050101", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1050101/answer", "answerText" : {"_value" : "<p>Porton Biopharma Ltd (PBL) are implementing a series of initiatives to increase capacity and supply in both the short and long term. These include the following:<\/p><p>- Extending operational activities to 24 hours a day, seven days a week to maximise fermentation of the product;<\/p><p>- Implementing an ongoing capital programme including construction of a new pharmaceutical fermentation facility. The facility was completed in April 2018 and is currently undergoing testing; it has an increased capacity fermentation suite which will enable PBL to manufacture at larger scale and is due to start producing product Q3 2019 for regulatory approval to market;<\/p><p>- A new filling and freeze-drying building was completed in February 2016. The installation of a new filling line which covers the entire process, including vial washing, filling, stoppering and freeze drying. The new line has been designed with systems which monitor all critical parameters throughout the process to accelerate batch release and will accommodate increased capacity. The beneficial use of this and the fermentation facility will coincide to maximise increased product output; and<\/p><p>- Sourcing replacement suppliers, including for new stoppers and new vials for the product, ensuring that maximum batch sizes can be achieved with minimal product rejects. This programme is complete.<\/p><p> <\/p><p>PBL has made significant investments into increasing product capacity and will continue to release future batches as soon as they become available to Jazz Pharmaceuticals (who are responsible for the packaging/distribution and allocation of worldwide product supply).<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-02-05", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-02-05T15:09:48.903Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-01-28", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Asparaginase"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 January 2019 to Question 207238 on Asparaginase, what steps Porton Biopharma will take to increase capacity of erwinase and better supply the (a) UK and (b) world market for the remainder of 2019.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "213322"}
    , {"_about" : "http://data.parliament.uk/resources/1039028", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1039028/answer", "answerText" : {"_value" : "<p>Erwinase is produced by Porton Biopharma Ltd (PBL) and is licensed and distributed by Jazz Pharmaceuticals under a global licencing agreement.<\/p><p> <\/p><p>Due to increased demand for Erwinase and because PBL are manufacturing at capacity, until increases in capacity are brought into beneficial use there will be occasional stock-outs.<\/p><p> <\/p><p>The product is currently in stock in the United Kingdom. The Department has been informed, it is likely there will be a short stock-out in early February 2019 and then a further batch is planned to be released to Jazz Pharmaceuticals, who are responsible for the packaging/distribution and allocation of worldwide product supply, anticipated to reach the UK market by mid-February 2019 which should last until the end of March 2019.<\/p><p> <\/p><p>The Department and Public Health England (PHE) are in close contact with, and have been kept informed by the PBL management of short periods of interrupted supply. PBL have and will be implementing a series of initiatives to increase capacity and better supply the market in both the short and long term. PBL are fully aware of the consequences that the unavailability of Erwinase has on patients and are absolutely committed to working with all involved to resolve any issues and be able to supply this critical medicine.<\/p><p> <\/p><p>The Department and PHE will continue to monitor the situation closely.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-01-18", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-01-18T12:18:00.113Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-01-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Asparaginase"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether Erwinase will be available for the treatment for children with acute lymphoblastic leukaemia between January 2019 and March 2019; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "207238"}
    , {"_about" : "http://data.parliament.uk/resources/1017502", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1017502/answer", "answerText" : {"_value" : "<p>This information is not held centrally.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-12-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-12-10T15:38:39.683Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-30", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what proportion of (a) leukaemia, (b) non-Hodgkin lymphoma, (c) Hodgkin lymphoma and (d) myeloma cases were diagnosed at each cancer stage in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "197620"}
    , {"_about" : "http://data.parliament.uk/resources/1002558", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1002558/answer", "answerText" : {"_value" : "<p>The NHS Long Term Plan provides an excellent opportunity to look at how cancer and other services can be further improved over the next decade. The plan is currently in development and will be published later in the year.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-14", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-14T11:29:49.547Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-06", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the ability of the NHS long-term plan to (a) tackle the evolving challenges of cancer and (b) ensure that people are able to access personalised and tailored support after they have finished cancer treatment itself.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "188796"}
    , {"_about" : "http://data.parliament.uk/resources/994628", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/994628/answer", "answerText" : {"_value" : "<p>NHS England is working with the manufacturers and National Health Service providers to prepare the NHS to begin delivering Chimeric Antigen Receptor T Cell (CAR-T) therapy - the first in a wave of treatments in a new era of personalised medicine and part of the NHS\u2019s long-term plan to upgrade cancer service. The first treatment that will be available to patient is tisagenlecleucel (Kymriah) as an option for treating children and young people up to 25 years old with B cell acute lymphoblastic leukaemia that is refractory, in relapsed post-transplant or in second or later relapse.<\/p><p> <\/p><p>NHS England anticipates that the National Institute for Health and Care Excellence will recommend this treatment for entry into the Cancer Drugs Fund in mid-November. If so, funding will be made immediately available, following a successful commercial deal with the manufacturer Novartis. We anticipate the first patients will begin their treatment in late November 2018. The phased implementation required by the manufacturer and the NHS means that full capacity to treat eligible patients will take some months to achieve and a National CAR-T Clinical Panel will convene in mid-November to assure equity of access and prioritise eligible patients.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-02", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-02T13:32:27.747Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-10-25", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Blood Cancer: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the NHS England news releases of 5 September and 5 October, when he plans to make CAR-T cell therapy available to (a) people aged under 25 with acute lymphoblastic leukaemia and (b) adult patients with diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after two or more previous therapies have failed.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "183918"}
    , {"_about" : "http://data.parliament.uk/resources/987817", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/987817/answer", "answerText" : {"_value" : "<p>NHS England is completely clear that the new 75% early diagnosis ambition announced by the Prime Minister covers all cancers, and not just the 10 currently included in the Public Health Outcomes Framework (PHOF) early diagnosis metric. NHS England is keen to work with the voluntary sector organisations and charities representing some of the other cancers not currently included in the PHOF metric on how we best measure progress towards the ambition moving forwards.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-10-23", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-10-23T16:57:18.817Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-10-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Blood Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether the initiatives announced by the Prime Minister on 3 October 2018 on early detection rates for cancer include blood cancer; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "179183"}
    , {"_about" : "http://data.parliament.uk/resources/982661", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/982661/answer", "answerText" : {"_value" : "<p>We have been informed by NHS England that since the implementation of the new Cancer Drugs Fund on 29 July 2016, 7,821 patients have been registered to receive treatment for a blood cancer, out of a total of approximately 25,700 patients who have been registered to receive cancer drug treatment. NHS England has advised that it is unable to provide a breakdown of patients registered to receive treatment with each medicine for reasons of commercial confidentiality.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-10-16", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-10-16T16:10:46.937Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-10-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Blood Cancer: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many blood cancer patients have received medicine funded by the Cancer Drugs Fund by each medicine since 2016.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "176228"}
    , {"_about" : "http://data.parliament.uk/resources/917376", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/917376/answer", "answerText" : {"_value" : "<p>NHS England has not specified estimates of individual conditions for referral into the Improving Access to Psychological Therapies (IAPT) integrated pathway. Local commissioning groups decide which pathways they integrate with based on their local prevalence and local intelligence data.<\/p><p> <\/p><p>Similarly, the NHS Digital IAPT dataset does not collect information on patients with a diagnosis of cancer, or types of cancer.<\/p><p> <\/p><p>There are currently no national plans to assess the effectiveness of the IAPT long-term health conditions pathway on people affected specifically by blood cancer. However there is robust evidence that by using the National Institute for Health and Care Excellence approved psychological therapies in addressing the mental health issues of those people with long term conditions earlier, talking therapies help to improve patients\u2019 health outcomes so that they become less reliant on primary and emergency care and importantly, help patients to self-manage their long-term conditions more confidently.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-06-12", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "150003"}
        , {"_value" : "150004"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-06-12T13:56:50.323Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-06-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Blood Cancer: Mental Health Services"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of people with blood cancer that will be referred into the Improving Access to Psychological Therapies integrated pathway as a result of the NHS Digital pilot data, published on 10 May 2018.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "150002"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&_page=1&answer.answeringMemberPrinted=Steve+Brine", "page" : 0, "startIndex" : 1, "totalResults" : 45, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}